J&J’s new ketamine-like melancholy drug Spravato given to sufferers
Metropolis on Could 21.
Spravato’s negative effects embrace sedation and dissociation. It additionally carries the potential threat of misuse and abuse. Acknowledging these elements, the FDA stipulated Spravato should be administered in a medically supervised health-care setting the place sufferers are monitored. Pharmacies, physician’s workplaces and clinics additionally should be licensed.
In somewhat greater than a month, J&J has licensed as much as 800 websites, placing the corporate “nicely on observe” with its plans for the yr, Jennifer Taubert, govt vice chairman of prescription drugs advised analysts on a name Tuesday discussing first-quarter earnings outcomes. She mentioned various sufferers have obtained their first dose with some receiving a number of doses.
“So we imagine that we’re off to a really, very robust begin with Spravato, and that it’s going to be an vital development driver for us,” she mentioned.